Insight

Nicholas Hornstein: The first trial to demonstrate benefit of systemic therapy in appendiceal cancer

Photo from Cancer Research Communications/X

May 22, 2024, 01:03

Nicholas Hornstein: The first trial to demonstrate benefit of systemic therapy in appendiceal cancer

Nicholas Hornstein, Oncology Fellow at MD Anderson Cancer Centre, shared a post by Cancer Research Communications on X, adding:

“Pleased to announce the first trial to demonstrate benefit of systemic therapy in appendiceal cancer. Atezolizumab and Bevacizumab; significantly improved PFS compared to synthetic cohort.

Median PFS 18.3 vs 4.4 months. Thanks to John Paul Shen and Kanwal Raghav for mentorship.” .

Quoting Cancer Research Communications’ post:

“Just published: Efficacy and safety of atezolizumab and bevacizumab in appendiceal adenocarcinoma, by Nicholas Hornstein et al.”

Source: Nicholas Hornstein/X and Cancer Research Communications/X

appendiceal adenocarcinoma appendiceal cancer atezolizumab Bevacizumab cancer Cancer Research Communications John Paul Shen Kanwal Raghav MD Anderson Cancer Centre Nicholas Hornstein OncoDaily Oncology

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

Former Disney CEO Bob Chapek Appointed Senior Adviser at SCAN Group

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

Special Coverage